Patients with Pathological Stage N2 Rectal Cancer Treated with Early Adjuvant Chemotherapy Have a Lower Treatment Failure Rate

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2017 Mar 11

PMID 28279170

Authors

Yan-Ru Feng

Jing Jin

Hua Ren

Xin Wang

Shu-Lian Wang

Wei-Hu Wang

Yong-Wen Song

Yue-Ping Liu

Yuan Tang

Ning Li

Xin-Fan Liu

Hui Fang

Zi-Hao Yu

Ye-Xiong Li

Affiliations

Soon will be listed here.

Abstract

Background: In this era of oxaliplatin-based adjuvant therapy, the optimal sequence in which chemoradiotherapy should be administered for pathological stage N2 rectal cancer is unknown. The aim of this study was to investigate this sequence.

Methods: In the primary adjuvant concurrent chemoradiotherapy (A-CRT) group (n = 71), postoperative concurrent chemoradiotherapy was administered before adjuvant chemotherapy. In the primary adjuvant chemotherapy (A-CT) group (n = 43), postoperative concurrent chemoradiotherapy was administered during or after adjuvant chemotherapy. Postoperative radiotherapy comprised 45-50.4 Gy in 25-28 fractions. Concurrent chemotherapy comprised two cycles of oral capecitabine (1,600 mg/m) on days 1-14 and 22-35. Patients receiving adjuvant chemotherapy with four or more cycles of XELOX (oxaliplatin plus capecitabine) or eight or more cycles of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) were included.

Results: Between June 2005 and December 2013, data for 114 qualified rectal cancer patients were analyzed. The percentages of patients in whom treatment failed in the A-CRT and A-CT groups were 33.8% and 16.3%, respectively (p = 0.042). More patients had distant metastases in the A-CRT group than in the A-CT group (32.4% vs. 14.3%, p = 0.028). Multivariate analysis indicated that the sequence in which chemoradiotherapy was administered (A-CT vs. A-CRT) was an independent prognostic factor for both estimated disease-free survival [hazard ratio (HR) 0.345, 95% confidence interval (CI) 0.137-0.868, p = 0.024] and estimated distant metastasis-free survival (HR 0.366, 95% CI 0.143-0.938, p = 0.036).

Conclusions: In pathological stage N2 rectal cancer patients, administering adjuvant chemotherapy before chemoradiotherapy led to a lower rate of treatment failure, especially with respect to distant metastasis. Adjuvant chemotherapy prescribed as early as possible might benefit this cohort of patients in this era of oxaliplatin-based adjuvant therapy.

References

Hong Y, Nam B, Kim K, Kim J, Park S, Park Y . Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014; 15(11):1245-53. DOI: 10.1016/S1470-2045(14)70377-8. View

Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R . XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer. 2011; 105(1):58-64. PMC: 3137415. DOI: 10.1038/bjc.2011.201. View

Garcia-Aguilar J, Chow O, Smith D, Marcet J, Cataldo P, Varma M . Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015; 16(8):957-66. PMC: 4670237. DOI: 10.1016/S1470-2045(15)00004-2. View

Twelves C, Scheithauer W, McKendrick J, Seitz J, Van Hazel G, Wong A . Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 2011; 23(5):1190-1197. DOI: 10.1093/annonc/mdr366. View

Lee J, Lee J, Ahn J, Bahng H, Kim T, Kang Y . Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report. J Clin Oncol. 2002; 20(7):1751-8. DOI: 10.1200/JCO.2002.07.037. View

Jin J, Li Y, Liu Y, Wang W, Song Y, Li T . A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer. Int J Radiat Oncol Biol Phys. 2005; 64(3):725-9. DOI: 10.1016/j.ijrobp.2005.08.017. View

Kim H, Chie E, Ahn Y, Kim K, Park W, Yoon W . Impact on Loco-regional Control of Radiochemotherapeutic Sequence and Time to Initiation of Adjuvant Treatment in Stage II/III Rectal Cancer Patients Treated with Postoperative Concurrent Radiochemotherapy. Cancer Res Treat. 2014; 46(2):148-57. PMC: 4022823. DOI: 10.4143/crt.2014.46.2.148. View

Tiselius C, Gunnarsson U, Smedh K, Glimelius B, Pahlman L . Patients with rectal cancer receiving adjuvant chemotherapy have an increased survival: a population-based longitudinal study. Ann Oncol. 2012; 24(1):160-5. DOI: 10.1093/annonc/mds278. View

Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C . Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009; 27(19):3109-16. DOI: 10.1200/JCO.2008.20.6771. View

10.

Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R . Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008; 26(12):2006-12. DOI: 10.1200/JCO.2007.14.9898. View

11.

Jin J, Li Y, Wang J, Wang W, Liu Y, Wang K . Phase I study of oxaliplatin in combination with capecitabine and radiotherapy as postoperative treatment for stage II and III rectal cancer. Int J Radiat Oncol Biol Phys. 2008; 72(3):671-7. DOI: 10.1016/j.ijrobp.2008.01.057. View

12.

Akagi Y, Shirouzu K, Fujita S, Ueno H, Takii Y, Komori K . Benefit of the measurement of mesorectal extension in patients with pT3N1-2 rectal cancer without pre-operative chemoradiotherapy: Post-operative treatment strategy. Exp Ther Med. 2013; 5(3):661-666. PMC: 3570185. DOI: 10.3892/etm.2012.858. View

13.

Roels S, Duthoy W, Haustermans K, Penninckx F, Vandecaveye V, Boterberg T . Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys. 2006; 65(4):1129-42. DOI: 10.1016/j.ijrobp.2006.02.050. View

14.

Biagi J, Raphael M, Mackillop W, Kong W, King W, Booth C . Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA. 2011; 305(22):2335-42. DOI: 10.1001/jama.2011.749. View

15.

Kusters M, Valentini V, Calvo F, Krempien R, Nieuwenhuijzen G, Martijn H . Results of European pooled analysis of IORT-containing multimodality treatment for locally advanced rectal cancer: adjuvant chemotherapy prevents local recurrence rather than distant metastases. Ann Oncol. 2009; 21(6):1279-1284. DOI: 10.1093/annonc/mdp501. View

16.

Rodel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D . Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015; 16(8):979-89. DOI: 10.1016/S1470-2045(15)00159-X. View

17.

Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R . Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351(17):1731-40. DOI: 10.1056/NEJMoa040694. View

18.

Kim T, Lee J, Lee J, Ahn J, Kang Y, Lee K . Randomized trial of postoperative adjuvant therapy in Stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: 10-year follow-up. Int J Radiat Oncol Biol Phys. 2010; 81(4):1025-31. DOI: 10.1016/j.ijrobp.2010.07.012. View

19.

Yothers G, OConnell M, Allegra C, Kuebler J, Colangelo L, Petrelli N . Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011; 29(28):3768-74. PMC: 3188282. DOI: 10.1200/JCO.2011.36.4539. View

20.

Deng Y, Chi P, Lan P, Wang L, Chen W, Cui L . Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III.... J Clin Oncol. 2016; 34(27):3300-7. DOI: 10.1200/JCO.2016.66.6198. View